Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...

What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der ...

Galderma’s Nemluvio (nemolizumab) has shown rapid relief of itch, as well as improvement in sleep, in patients with atopic ...

Health equity is an ambitious goal, but the drive to deliver life-changing innovation to all eligible patients is ...

The industry is now entering the next era by embedding AI directly into the software field teams’ use every day. The step ...

Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

When influence outpaces expertise However, the rise of health content on social media has also fuelled the parallel problem ...

Building a trusted data foundation The starting line for any successful AI journey is data readiness and quality. Before ...

Creative agency Havas Life London has launched an impactful new campaign, ‘The World’s Rarest Disease’, highlighting the ...

Clicks and engagement only tell part of the story. In this webinar, pharma leaders discuss how to move beyond traditional ...

AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...

At Avalere Health, we have identified six crucial elements of a successful launch, driven by insight, integrated working, ...